INSMED INC (INSM)

Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Top Buys by Directors: Sharoky, M.D.'s $385.8K Bet on INSM

INSM Crosses Above Key Moving Average Level

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

—Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW...

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"

—Early-Stage Research Pillar Anticipated to Generate at Least Six Investigational New Drug (IND) Applications by End of 2025— —Company Reveals Select Initial...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update

—Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024—...

Insmed to Host Investor and Analyst Event on May 8, 2023

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

—Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of...

First Week of April 21st Options Trading For Insmed (INSM)

Analysts and Executives Converge February 2nd at the 30th Annual Emerald Groundhog Day Investment Forum

Insmed Breaks Above 200-Day Moving Average - Bullish for INSM

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference

—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses— —Treatment...

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed To Present at the Nasdaq 47th Investor Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

First Week of INSM January 2023 Options Trading

Top Buys by Directors: Lee's $796K Bet on INSM

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...